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The blood-brain barrier (BBB), constituted by an extensive network of endothelial
cells (ECs) together with neurons and glial cells, including microglia, forms the
neurovascular unit (NVU). The crosstalk between these cells guarantees a proper
environment for brain function. In this context, changes in the endothelium-microglia
interactions are associated with a variety of inflammation-related diseases in brain,
where BBB permeability is compromised. Increasing evidences indicate that activated
microglia modulate expression of tight junctions, which are essential for BBB
integrity and function. On the other hand, the endothelium can regulate the state
of microglial activation. Here, we review recent advances that provide insights into
interactions between the microglia and the vascular system in brain diseases such
as infectious/inflammatory diseases, epilepsy, ischemic stroke and neurodegenerative
disorders.
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INTRODUCTION
The cerebrovasculature plays a crucial role in oxygen and
nutrient delivery to the organ with the highest metabolic
demand in the body, the brain. Moreover, it has a vital func-
tion in maintaining a stable ionic environment and protect-
ing against neurotoxic substances critical for normal brain
development and function. Brain endothelial cells (ECs) are
especially suited for these functions. They act as a selective
physical barrier known as the blood brain barrier (BBB), a
unique specialized structure of the central nervous system
(CNS) capillary bed based on EC tight junctions, with no
endothelial fenestrae, and expression of specific membrane trans-
porters, thus ensuring homeostasis and proper functioning of
the brain. Brain ECs are closely associated and functionally
assembled in what is termed the “neurovascular unit”, com-
posed by ECs, neurons, pericytes and glia (Iadecola, 2004).
The neurovascular unit (NVU) is at the basis of neurovascu-
lar coupling, which allows cerebral blood flow to be locally
regulated according to neuronal activity in specific areas of
the brain, contributing to normal CNS functioning (Zlokovic,
2008).
In this review, we discuss current concepts underlying the
interactions between the vascular system and glial cells, in
particular, the microglia—the CNS resident macrophages—in
brain diseases such as infectious/inflammatory diseases, epilepsy,
ischemic stroke and neurodegenerative diseases.
MICROGLIA-ENDOTHELIUM INTERACTION DURING
DEVELOPMENT
During embryogenesis, the formation of the BBB is a gradual
process that starts with sprouting and invagination of newly
formed branches from the perineural vascular plexus through
angiogenesis (Ruhrberg and Bautch, 2013). At the distal end of the
growing capillary lies a specialized EC, known as tip cell (Gerhardt
et al., 2003), which guides the vascular sprout by integrating
external guidance cues as well as vascular endothelial growth
factor (VEGF) gradients in the extracellular matrix (Ruhrberg
et al., 2002; Gerhardt et al., 2003). Vascular plexus growth is
accomplished by halting tip cell migration, followed by tip cell
anastomosis and subsequent lumen formation (Lenard et al.,
2013). Finally, vessel stabilization and maturation depends on
the association of perivascular cells on the new sprouts (Lin-
dahl et al., 1997). The BBB properties are not intrinsic to CNS
ECs, as demonstrated by transplantation experiments using the
avian embryo model. Prospective abdominal vessels grafted in
contact with neural tissue display functional and histochemical
characteristics of the BBB (Stewart and Wiley, 1981). It has
been shown that formation of EC tight junctions occurs soon
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after invasion of the vessels into the developing neuroectoderm
(reviewed in Wolburg and Lippoldt, 2002). The ratio of pericyte
coverage is highest in the CNS microvessels, which are found
to be thoroughly covered by a perivascular astroglial sheath
(Mathiisen et al., 2010). Several studies have also shown that
components of the NVU such as pericytes and astrocytes play a
key role in regulating BBB maintenance and integrity (Janzer and
Raff, 1987; Armulik et al., 2010; Daneman et al., 2010). Taken
together, these results suggest that the interaction of the ECs with
the neural environment is at the basis of the properties of the
BBB.
Distinct immune cells within the CNS interact with the
BBB. Whereas blood-borne macrophages localize between the
vessel wall and the astrocytic endfeet at the meninges, choroid
plexus and perivascular spaces (reviewed in Ransohoff and
Engelhardt, 2012), recent in vivo studies present evidence that
resident microglia in the brain parenchyma also interact with
CNS microvessels suggesting that, besides an indisputable role
in CNS development and homeostasis (reviewed in Nayak et al.,
2014), those cells might be also playing a key role in regulating
BBB properties during embryogenesis and disease (Fantin et al.,
2010; Tammela et al., 2011). Microglia are the most abundant
CNS innate immune cells, which during embryogenesis migrate
from the yolk sac into the CNS parenchyma (Alliot et al., 1999).
Microglia cerebral colonization precedes EC sprouting into this
tissue (Cuadros et al., 1993; Checchin et al., 2006; Fantin et al.,
2010; Ginhoux et al., 2010) but soon after, they localize in tight
physical association with microvascular structures (Fantin et al.,
2010; Figure 1), suggesting that microglia may play a role in
angiogenesis as well as in conferring BBB properties to brain
microvessels. In addition, microglia associate with endothelial
tip cells, as demonstrated during embryonic brain and postna-
tal retinal angiogenesis (Fantin et al., 2010; Rymo et al., 2011;
Tammela et al., 2011). Fantin and collaborators present in vivo
data showing that during embryonic stages of CNS vascular-
ization, EC stabilization and fusion are mediated by resident
microglial cells (Fantin et al., 2010). Mice deficient for PU.1
(transcription regulator of CD11b and colony stimulating factor
(CSF)-1) have reduced microglia, but not circulating monocytes,
and present a decrease in embryonic CNS vascular connections.
Because microglia appear to be physically associated with tip cell
filopodia and the number of sprouts in not altered, the authors
suggest that microglia play a role in CNS angiogenesis by serving
as a bridge to promote tip cell fusion, vascular plexus growth
following sprouting induction and tip cell migration by VEGF
(Fantin et al., 2010). Similarly, specific depletion of microglia
using clodronate liposomes (CL2MDP-lip) results in decreased
vessel density in a mouse model of choroidal neovascularization
(Espinosa-Heidmann et al., 2003). Further in vivo evidence for
a role of microglia as a cellular chaperone controling the fusion
and stabilization of vascular sprouts during CNS vascularization
came from the observation that a subpopulation of F4/80/Tie-2
positive cells, specifically located near branching sites at the
vascular front during vascularization stages of the retina, express
VEGF-C. Despite increased vessel sprouting and filopodia bursts,
VEGF-C heterozygotes present delayed retinal vascularization and
decreased vessel branching density (Tammela et al., 2011). These
FIGURE 1 | Resident microglia associate with endothelium in the
cortical microvascular bed. Representative confocal image revealing close
interaction between microglia (IBA1, green) and endothelial cells
(IsolectinB4, red) in a 50 micron-cryopreserved cross-section of a
1 month-old mouse cortex. Scale bar: 25 µm. This study was approved by
the Ethics Committee of the Health Sciences Center at the Federal
University of Rio de Janeiro (Protocol No. DAHEICB 015). The “Principles of
laboratory animal care” (NIH publication No. 85–23, revised 1996)
guidelines as well as The Code of Ethics of EU Directive 2010/63/EU were
strictly followed for experiments.
F4/80-expressing cells present a ramified morphology, which is
typical of microglial cells. The retina is part of the CNS and
therefore also presents a proper blood barrier. Since the study
by Tammela et al. was performed without any damage to the
retinal blood barrier, and resident macrophages of the CNS are
microglial cells, it thus constitute further in vivo evidence for
microglia CNS endothelium interaction during early stages of
CNS vascularization.
Although a great deal of literature has demonstrated that
microglia play a role in CNS diseases where BBB breakdown is
a hallmark, little is known about a possible role of these cells
in inducing and/or maintaining BBB properties during CNS EC
development. The fact that microglia are present in the embryonic
CNS territory prior to endothelial invasion and that they partici-
pate in cerebrovasculature growth place the interactions between
microglia and CNS endothelium as a possible key mechanism in
BBB formation and regulation.
MICROGLIAL ACTIVATION AND THE IMPACT ON BBB
Microglia are the resident immune cells in the CNS and per-
form an essential role in the immune response, while they
are also an important component of the NVU (Spindler
and Hsu, 2012). Microglia become activated under brain
injury and immunological stimuli (Kreutzberg, 1996) and
undergo several alterations from a “resting state” to an active
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state (Hanisch and Kettenmann, 2007; Kettenmann et al.,
2011). This activation and consequent neuroinflammation are
substantially involved in the progression of neurodegenera-
tive diseases (McGeer and McGeer, 1995) and impairments
of the BBB have been observed in this context (Dickstein
et al., 2006; Zipser et al., 2007; Lassman et al., 2012;
Figure 2).
Recent studies suggest that microglial activation may be
related to BBB disruption. Sumi and collaborators evaluated
the effects of lipopolysaccharide (LPS), a microglial activator,
on BBB functions in an in vitro co-culture system using rat
brain microvascular endothelial cells (RBEC) and microglia.
Treatment with LPS on the outside of the insert (abluminal
side) in both RBEC monolayer and RBEC/microglia co-culture
showed no effect on transendothelial electrical resistance (TEER)
in the RBEC monolayer. However, when the LPS treatment
was performed on the RBEC/microglia co-culture, TEER was
decreased and this was dependent on the number of microglial
cells. Moreover, LPS had no effect on the permeability coef-
ficient of sodium-fluorescein (Na-F) in RBEC monolayer, but
in RBEC/microglia co-culture, LPS increased the Na-F per-
meability. The tight junctions and efflux transporters are the
main machinery underlying the BBB function (Liebner et al.,
2000; Rajasekaran et al., 2008). Immunostaining for the tight
junction proteins zonula occludens-1 (ZO-1), claudin-5 and
occludin exhibited a continuous distribution of these pro-
teins along cell border in RBEC co-cultured with microglia,
but when treated with LPS, this was changed to a expression
pattern that was restored to a linear shape by adding DPI,
a NADPH oxidase inhibitor. These results suggest that acti-
vated microglia probably produce reactive oxygen species (ROS),
through NADPH oxidase, and impair BBB function (Sumi et al.,
2010).
In fact, several neurodegenerative diseases include BBB dys-
function. For example, the disruption of BBB caused by oxidative
stress seems to be an important step to the development of these
disorders, since ROS have been shown to modulate BBB integrity
by transient activation of PI3K/AKT pathway via RhoA leading
to tight junction leakage (Schreibelt et al., 2007). In addition, the
NADPH oxidase system of microglial cells seems to be the main
producer of superoxide anion (O2−), causing BBB permeability
(Block and Hong, 2005; Rojo et al., 2014). When microglial
activation was inhibited with minocycline or superoxides pro-
duced by NADPH oxidase were blocked with apocynin, the BBB
constituents were preserved in vitro whereas BBB disruption and
hemorrhage were reduced in vivo (Yenari et al., 2006).
Furthermore, to clarify the involvement of tumor necrosis fac-
tor α (TNF-α) released from activated microglia on BBB integrity,
FIGURE 2 | In normal conditions, neurons and glial cells interact
together to promote the homeostasis of the brain. When an injury
occurs in the brain, microglia and astrocytes are capable of producing
cytokines and chemokines and stimulate the adhesion molecules on ECs,
allowing the migration of myeloid cells from the blood into the brain. In
particular, microglial cells become activated with LPS stimulus and
produce ROS through the action of NADPH oxidase, TNFα, IL-1β, that
impairs BBB function altering the expression of important molecules in
the BBB integrity, such as ZO-1, claudin-5, occluding and P-gp.
CD200-deficient mice showed an increased BBB permeability that
possibly favors T cell entrance in the brain followed by an increased IFNγ
expression that activates microglial cells and enhance the release of
microglial activation markers including TNFα, IL-6, contributing to keeping
the BBB injury.
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an in vitro co-culture system with mouse brain capillary ECs
(MBEC4) and microglia showed that the permeability of MBEC4
cells to Na-F was increased when microglial cells were activated
by LPS and it was blocked by a neutralizing antibody against
TNF-α, indicating that TNF-α contributes to BBB dysfunction
(Nishioku et al., 2010). On the other hand, ICAM-1 plays an
important role in cell-cell adhesive interactions and its expres-
sion in cerebral microvessels is low under normal conditions.
However, ICAM-1 expression increases in the presence of proin-
flammatory mediators, such as TNF-α, interleukin (IL)-1β, IL-
4 and interferon- γ (IFNγ). The correlation between induction
of ICAM-1 expression and increased BBB permeability has been
shown in acute inflammation. In an effort to understand by
which pathways the peripheral inflammation affects BBB function
and structure, Huber and collaborators investigated the effect of
λ-carrageenan-induced inflammatory pain (CIP) on the ICAM-
1 expression in the BBB. The induction of ICAM-1 was region-
specific and directly correlated with an increase in microglial
activation (Huber et al., 2006). Moreover, the decreased expres-
sion of CD200, which occurs with ageing or in the brain of
Alzheimer’s Disease (AD) patients, is associated with microglial
activation. CD200 is expressed on several cell types and its
receptor, CD200R, is expressed on microglia. This interaction
has been shown to be important in modulating inflammation
and macrophage function. Denieffe and collaborators observed
an increased expression of TNF-α and IFNγ in CD200 defi-
cient mice, molecules known to promote classical activation of
microglia. The increase of IFNγ levels was probably owing to
the entrance of T cells and macrophages into the CNS facili-
tated by an increased BBB permeability, since IFNγ is normally
not produced by resident cells in the brain (Denieffe et al.,
2013).
Further evidence for the involvement of microglia on BBB
opening was provided by the analysis of AD brain tissue, which
showed overlap areas of microgliosis with fibrinogen immunore-
activity. Moreover, these representative patterns of staining
were in apparent association with blood vessels. These findings
incited in vivo experiments using intra-hippocampal injections of
Aβ¬1–42 in rat brains, which caused time-dependent increase in
expression of fibrinogen and microgliosis compared to the con-
trol. Moreover, IgG immunoreactivity was minimal in the control
but significantly increased after Aβ¬1–42 injection. Inclusion
of anti-Mac-1, a neutralizing monoclonal antibody that blocks
the binding of fibrinogen to Mac-1 on microglia and inhibits
microglial activation, was highly effective in decreasing IgG after
Aβ¬1–42 injection. In these experiments, the permeability of
BBB was determined by levels of IgG infiltration consistent with
reduced microglial reactivity associated to an increased BBB
preservation (Ryu and McLarnon, 2009). Therefore, microglial
responses to Aβ¬1–42 can promote vascular changes that induce
BBB breakdown plasma protein infiltration (Ryu and McLarnon,
2009).
Considering all the studies mentioned above, microglial acti-
vation impairs BBB function by the release of various molecules
leading to a hyperpermeability condition associated with inflam-
mation that is similar to what occurs in certain neurodegenerative
disorders, including AD and Multiple Sclerosis (MS). We do not
discard the entering and the action of bone marrow derived
myeloid cells into the CNS in inflammatory conditions, but
undoubtedly microglia certainly play an important role in these
pathologies (Perry et al., 2010; Graeber et al., 2011).
An intact BBB is essential to control leukocyte trafficking
either to immune response during brain infection, or after brain
damage when microglial cells and macrophages must clear the
debris (Shechter and Schwartz, 2013). On the other hand, the
brain inflammatory response to antigen infiltration (virus, bac-
teria or fungus) triggered by activated microglia may result in
aberrant expression of several chemokines, leading to alterations
in BBB permeability (Buckner et al., 2006; Obermeier et al.,
2013).
The microglial immune response to a brain infection is a
complex event that involves several chemokines, particularly
the monocyte chemoattractant protein-1 (MCP-1; Andjelkovic
et al., 1999). MCP-1 is produced by several cell types includ-
ing microglia, monocytes, macrophages, neurons, astrocytes and
brain microvessel endothelial cells (BMECs; Andjelkovic et al.,
1999; Andjelkovic and Pachter, 2000; Mahad and Ransohoff,
2003), and exerts biological functions by binding to its high
affinity receptor CCR2, expressed by microglia, astrocytes
and BMECs in the brain microenvironment (Banisadr et al.,
2002; Ge et al., 2008). In vivo studies using MCP-1 knockout
mice showed that this chemokine is important to maintenance
of BBB integrity (Yao and Tsirka, 2011). On the other hand,
the up-regulation of MCP-1 in the brain microenvironment dur-
ing inflammatory response probably disrupts BBB integrity by
redistribution of tight junction proteins, such as occludin and
claudin-1, 5 and 11 and reorganization of the actin cytoskeleton
in brain microvascular ECs (Stamatovic et al., 2003, 2005, 2006;
Dimitrijevic et al., 2006).
Patients with bacterial/viral meningitis exhibit severe BBB
impairment in the course of the disease resulting in brain
edema, associated with high levels of TNF-α (Sharief et al., 1992;
Glimåker et al., 1993; Leppert et al., 2000; Brivet et al., 2005;
Ubenauf et al., 2007; Mook-Kanamori et al., 2011). During CNS
infection by the human immunodeficiency virus (HIV), perivas-
cular macrophages and microglia are the predominant cell types
initially infected by HIV (Wiley et al., 1986). Infected monocytes
are more responsive to MCP-1 than normal monocytes, which
possibly increase their ability to cross the BBB through the accu-
mulation of adhesion molecules, for instance E-selectin, in the
interface between ECs from the BBB and monocytes, resulting
in the infection of resident microglia and macrophages (Buckner
et al., 2006; Eugenin et al., 2011). Cytokines are highly expressed
in HIV-infected microglia/macrophage, leading in turn to an
overexpression of IFNγ and TNF-α, inducing EC death pathway,
and finally BBB dysfunction. Besides cytokine overexpression,
viral proteins, mainly Tat, stimulate cyclooxygenase-2 (COX-2)—
an enzyme produced in response to TNF-α during inflammation,
associated with decrease of ZO-1 expression in the tight junctions,
which leads to BBB rupture and various neurological disorders
(Wang et al., 2008; Strazza et al., 2011).
In traumatic brain injury, the post-traumatic inflammatory
response is related mainly to cytokine and metalloproteinase
(MMP) expression in the lesion site, where IL-1β is associated
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with ZO-1 loss and tight junction redistribution (Bolton et al.,
1998; Obermeier et al., 2013). The increased levels of MMPs,
particularly MMP-2, 3 and 9, have also been observed, produced
mainly by microglia (Truettner et al., 2005). These proteins dis-
rupt the basal lamina proteins and degrade the tight junction
complexes, resulting in BBB breakdown and severe neurologi-
cal disorders after traumatic injury (Cunningham et al., 2005;
Yang et al., 2007). Using a rat model of traumatic brain injury,
Readnower and collaborators showed that microglial activation-
derived oxygen free radicals as well as subsequent reaction prod-
ucts, hydrogen peroxide and nitric oxide (NO), have the potential
to harm cells, contributing to oxidative damage, neurodegen-
eration and BBB impairment (Readnower et al., 2010; Briones
et al., 2011; Xiong et al., 2012). One of the consequences of
oxidative stress is the peroxidation of membrane polyunsaturated
fatty acids, giving rise to active aldehydes significantly increasing
ECs permeability (Chodobski et al., 2011). The toxicity of oxygen
reactive species is observed in other cerebral disorders, such
as ischemia (Massberg et al., 2002). During cerebral ischemia,
there is platelet accumulation in microvessels, which triggers
EC activation and increases ICAM-1 expression, enhancing the
neutrophil infiltration in the brain parenchyma, contributing to
cerebrovascular inflammation (Thornton et al., 2010).
EPILEPSY
According to the International League Against Epilepsy (ILAE)
and the International Bureau for Epilepsy (IBE) a seizure
is characterized by transient abnormal excessive or hypersyn-
chronous neuronal activity in the CNS, which leads to specific
signs and symptoms. The occurrence of more than one spon-
taneous seizure characterizes epilepsy, a brain disorder where
there is enduring predisposition to generate such seizures (Fisher
et al., 2005). Despite neurons being the “effector” cells in
epilepsy, the importance of cells from the NVU, specially glial
cells, in the pathogenesis of this disease becomes increasingly
prominent.
Many works have acknowledged the role of neuroinflamma-
tion in the pathogenesis of seizures, but little is known about the
mechanisms that start the inflammatory process in the CNS. On
one hand, it is known that seizures can occur in many CNS dis-
eases where inflammation contributes to its pathophysiology such
as traumatic brain injury (Kadhim et al., 2008), ischemia (Denes
et al., 2010; Downes and Crack, 2010), MS (Centonze et al., 2010)
and AD (Eikelenboom et al., 2011). On the other hand, there is
growing evidence that peripheral inflammation causes a “mirror”
inflammatory response in the CNS, characterized by microglial
and endothelial cytokine production and invasion of peripheral
leukocytes (Quan et al., 1999; Qin et al., 2007; Riazi et al., 2008;
Pyter et al., 2009), which can in turn reduce the threshold for
seizure induction.
In the epileptic brain a key neuroinflammatory mediator is
IL-1β, produced by microglia and astrocytes in great amounts
(Ravizza et al., 2008a). Neurons and cells from the NVU (ECs,
microglia and perivascular astrocytes) express IL-1R1 receptor
and therefore, mediate the effects of this cytokine (Vezzani et al.,
2008). In the context of seizures, astrocytes and neurons also
produce other substances that modulate microglial function, such
as TGF-β, ATP, HMGB1 (a chromatin associated nuclear protein)
and fractalkine (CX3CL1; Verderio and Matteoli, 2001; Rodgers
et al., 2009; Aronica et al., 2010, 2012; Dubé et al., 2010; Vezzani
et al., 2011).
Microglial and astrocytic IL-1β act directly on the endothe-
lium, altering BBB permeability and contributing to epilepto-
genesis. IL-1R1 activation on ECs increases BBB permeability
through downregulation of tight junction proteins, mainly ZO-
1, and upregulation of NO and MMPs (Ravizza et al., 2008a,b;
Morin-Brureau et al., 2011; Librizzi et al., 2012). This BBB
damage “from the inside” is associated with several downstream
effects, all of which directly affect neuronal activity (Kofuji and
Newman, 2004; Coulter and Eid, 2012). Endothelial cells activated
by IL-1 β also have increased expression of adhesion molecules
(ICAM-1, VCAM-1, E-Selectin and P-Selectin) that promote
leukocyte adhesion, rolling and arrest in their luminal surface,
releasing cytokines/proteases and damaging the BBB “from the
outside”. This damage “from the outside” further alters BBB’s
permeability to ions and proteins, contributing to sustain the
mechanisms of hyperexcitability (Fujiwara and Kobayashi, 2005;
Fabene et al., 2008; Kim et al., 2009).
The role of the other inflammatory mediators produced by
microglia and astrocytes in the context of hyperexcitability is
not as fully understood as IL-1β’s. Vascular endothelial growth
factor, IL-6, TNF-α, CCL-2 and prostaglandins were also shown
to be important for the development of seizures: IL-6 and CCL-2,
for example, are important for chemoattraction of peripheral
leukocytes that interact with ECs and contribute to BBB damage
“from the outside” (Obermeier et al., 2013). Vascular endothelial
growth factor, contributes to BBB damage by inducing downreg-
ulation of ZO-1, besides promoting microvascular proliferation
(angiogenesis) via VEGFR2 on ECs (Ravizza et al., 2008a; Morin-
Brureau et al., 2011; Librizzi et al., 2012). These studies further
suggest the importance of the interaction between microglia and
ECs in epilepsy.
In this context, the importance of microglial and astrocytic
activation is corroborated by the control of epileptic
syndromes resistant to conventional anti-epileptic drugs by
anti-inflammatory or immunosuppressive treatments (Najjar
et al., 2011). For example, intravenous immunoglobulin (IVIG)
can reduce cytokine production and astrocyte activation and,
therefore, suppresses seizures. Intravenous immunoglobulin
increases the circulating levels of IL-1R antagonist (IL-1Ra),
blocking IL-1β signaling (Crow et al., 2007; Mikati et al., 2010; Li
et al., 2012). In addition, there are also ongoing clinical trials with
VX-765, a selective inhibitor of caspase-1, the enzyme that cleaves
the precursor form of IL-1β into the active peptide, and therefore
reduces its production (Ravizza et al., 2008b; Maroso et al., 2011;
Vezzani et al., 2011). Taking all the recent data into consideration,
we can suggest that the cells of the NVU, specially glial cells, have
an overwhelming importance in epileptogenesis. Excitation and
inflammation, traditionally considered independent pathways,
are now understood as overlapping and interconnected processes;
as inflammation can promote excitability, and so can excitability
promote inflammation. These current findings show the
increasing importance of the inflammatory pathways activated by
microglial cells in inducing BBB dysfunction, which contributes
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 362 | 5
da Fonseca et al. Microglia and blood-brain barrier
to epileptogenesis. Furthermore, this understanding is leading to
the development of therapeutic strategies attempting to disrupt
this self-perpetuating process of inflammation-hyperexcitability,
aiming to improve the control of drug-resistant epilepsies.
STROKE
The term stroke comprises a heterogeneous spectrum of
conditions that have in common the interruption of blood supply
to the brain parenchyma. This deficit in the blood flow leads to
brain damage that is divided in two regions: the rapidly, severely
injured necrotic core and the surrounding penumbra region (Liu
et al., 2010; Ronaldson and Davis, 2012). The mechanisms of
brain death in the ischemic core are mainly related to direct
cellular damage due to oxygen and glucose deprivation, as a
collapse of ion gradients and excitotoxicity (Adibhatla et al., 2006;
Arai et al., 2011; Ronaldson and Davis, 2012). The importance of
the crosstalk between neurons, ECs and glial cells (in particular
microglia and astrocytes) becomes more prominent in the
context of the penumbra region, a functionally impaired, but not
dead area of the ischemic brain, which is pathophysiologically
characterized by hypoxia/reoxygenation stress, BBB disruption,
edema and active inflammation (Lo et al., 2005).
The re-establishment of the blood flow to the penumbra is
responsible for most of the cellular damage observed in the
ischemic stroke, associated with neuronal apoptosis, increase in
cellular distress secondary to ROS production, and decreased con-
centrations of antioxidants (GSH). In this context, it is detachable
the increased expression of hypoxia-inducible factor-1 (HIF-1)
and nuclear factor-κB (NF-κB), in endothelial and glial cells,
especially microglial cells. The pathways up-regulated by these
transcription factors are involved in disruption of the BBB and
neuroinflammation (Witt et al., 2005; Lochhead et al., 2010;
Yang and Rosenberg, 2011). Besides that, activated microglia
itself produce ROS and NO, further contributing to endothelial
and neuronal damage, microglial activation, and perpetuation of
stress.
One of the key components of the cell death cascades in stroke
is neuroinflammation, where the main players are microglial cells
and the peripheral leukocytes, especially neutrophils and mono-
cytes/macrophages. After the ischemic insult, the recruitment
of immune cells occurs in a biphasic dynamics. In the acute
phase (within minutes), microglial cells are rapidly recruited to
the injury site, due to the immediate release of cytokines and
chemokines. These cells are activated, enhancing the release of
ROS (through NADPH oxidase and MPO), cytokines (i.e., IL-1β,
IL-6 and TNF-α) and chemokines (MCP-1, CXCL-1 and MIP-
1α). At this time, ECs are also stimulated by these mediators,
and the expression of adhesion molecules ICAM-1, P-Selectin
and VCAM is upregulated, mainly by activation of the NF-κB
pathway. These molecules are also upregulated in the circulat-
ing leukocytes, thus enhancing cell migration in the late phase
(Kunsch and Medford, 1999; Jin et al., 2010; Enzmann et al.,
2013; Obermeier et al., 2013). In this late phase, neutrophils
and peripheral macrophages become important mediators of the
neuroinflammation and propagation of the acute phase events,
by sustaining the production of proinflammatory mediators and
ROS, besides inducing and activating MMPs (Jin et al., 2010).
In vivo models helped clarifying the kinetics of the immune
cells in ischemic stroke: Denes and colleagues used cell tracking
techniques and MRI imaging to describe that, despite of BBB
breakdown caused by transient middle cerebral artery occlusion
(tMCAo), the infiltration of neutrophils was more prominent
only in longer periods of MCAo, with extensive BBB damage.
Also, very few infiltrating exogenous macrophages were observed
over the first 72 h period and, instead, a profound increase in
proliferating resident microglia cells was observed (Denes et al.,
2007). However, microglia also remains as an important effector
in the late phase, as Ekdahl and colleagues reported an increased
number of activated microglial cells up to 16 weeks after two
hour MCAO in rats (Ekdahl et al., 2009). Therefore, these works
support the concept that microglia are a crucial mediator of the
neuroinflammatory response in the CNS after ischemic injury,
both in early and late phase stages.
Recently, the neuroinflammatory state was shown to activate
the c-Jun N-terminal kinase (JNK) pathway not only in microglia
but also in ECs, leading to microglial and endothelial activa-
tion with direct and microglial-induced BBB disruption, further
cytokine production and perpetuation of the neuroinflammatory
process (Tu et al., 2011; Wang et al., 2012).
BBB disruption is another key event in the pathogenesis of
stroke, as it can worsen the clinical picture of the patients by
the formation of intracerebral vasogenic edema and hemorrhagic
transformation. As it occurs in neuroinflammation, BBB disrup-
tion has a biphasic dynamics. The early opening (12–48 h) of
the BBB is mainly caused by oxidative stress, being ROS the
most important mediator. They activate the latent MMP-2 min
after the ischemic insult, and are produced by microglia and
astrocytes through the HIF-1α pathway (Yang and Rosenberg,
2011; Obermeier et al., 2013). Another phenomenon observed in
this early phase is the release of cytokine pools that were trapped
by BBB ECM (“molecule trapping”), that activate glial and ECs
and contribute to the recruitment of peripheral immune cells
(Obermeier et al., 2013). In addition, ROS and NO can also
reorganize the cytoskeleton of ECs and modulate tight junction
proteins claudin-5 and occludin (Yamagata et al., 2004; Schreibelt
et al., 2007) activate microglial cells; and up-regulate inflamma-
tory mediators in the first 48 h. This microglial activation by
ROS enhances the production of more ROS, intensifying the early
response.
A delayed secondary opening of the BBB occurs after 48 to
72 h and results from the sustained inflammatory response in
the brain parenchyma. In this phase, MMPs are important medi-
ators: microglial ROS, especially superoxide radical O2−, increase
vascular permeability also by stimulating MMP-2/MMP-3/MMP-
9 production by microglia, astrocytes and ECs (Gottschall and
Deb, 1996; Asahi et al., 2001; Rosenberg et al., 2001), contributing
to hemorrhagic transformation and vasogenic edema. MMPs are
further stimulated by NK-κB and HIF-1α and disrupt TJ proteins
(as ZO-1, claudin-5 and occludin), rendering the BBB leaky,
downstream effects which were shown to be reverted by blocking
NOS (Yang and Rosenberg, 2011; Gu et al., 2012; Obermeier et al.,
2013).
The activation of the previously stated pathways lead
microglial cells to produce a variety of molecules, such as TNF-α,
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IL-1 β, IL-6, NO and insulin-like growth factor 1 (IGF-1) that
interfere with BBB permeability. Apart from the effects of MMPs,
microglial-induced late-phase BBB disruption is due to direct
effects on ECs: IL-1β and TNF-α downregulate tight junction
proteins expression in ECs (Yamagata et al., 2004; Jiao et al., 2011)
and, together with IL-6, modulate the expression of adhesion
molecules (ICAM-1 and VCAM; Hallenbeck, 2002). These actions
not only help enhancing the influx of peripheral leukocytes, but
also contribute to the formation of vasogenic edema by allowing
the diffusion of sodium and water (Sandoval and Witt, 2008).
These mediators also indirectly lead to BBB damage, by acting
not on ECs, but on different components of the NVU: activating
MMPs and acting on astrocytes and pericytes through ROS, NO
and cytokines.
Blood-derived macrophages and microglia appear to have
many functions in the dynamic process of CNS injury and
repair, affecting BBB permeabilization, which in turn can aggra-
vate stroke (Hallenbeck, 2002; Sandoval and Witt, 2008; Jiao
et al., 2011). Preclinical and clinical studies corroborate this
observation: minocycline, a member of the tetracycline antibiotic
family, inhibits activation of microglia and brain infiltrating
blood-derived macrophages and protects cultured neurons from
excitotoxic insults by preventing microglial generation of glu-
tamate, IL-1β and NO (Yrjänheikki et al., 1998, 1999; Tikka
et al., 2001). These anti-inflammatory properties of minocycline
are thought to act through inhibition of p38MAPK and MMP-9
(Tikka et al., 2001; Koistinaho et al., 2005). Inhibiting microglial
activation may limit BBB disruption and reduce vasogenic edema
in the context of ischemic stroke, reducing the volume of ischemic
tissue and neuronal deficits, as well as preventing hemorrhagic
transformation (Tikka et al., 2001; Yenari et al., 2006). So far,
minocycline has been incorporated into two clinical trials involv-
ing ischemic stroke patients, demonstrating that minocycline
administration (both alone and in combination with Fibrinoly-
sis) improved neurological functional outcome following stroke
(Fagan et al., 2011).
On the other hand, some groups advocate the concept that
microglial cells are important for recovery from ischemic damage.
Some in vitro and in vivo studies have shown the role of IGF-1
in promoting neuroprotection and neuroregeneration (Li et al.,
2010; Selvamani et al., 2012; Sohrabji and Williams, 2013; Bake
et al., 2014). It has also been shown that the selective ablation
of proliferating microglial cells in a transgenic mouse model
exacerbates the extent of ischemic injury (Lalancette-Hébert et al.,
2007). Besides that, Kitamura and colleagues demonstrated in a
rat model that the intracerebroventricular injection of microglia
protected the BBB and neurons against focal brain ischemia
(Kitamura et al., 2004). All these data suggest that microglia has a
role in the EC damage and BBB disruption in stroke, making these
cells a possible target to minimize the ischemic damage in stroke
patients.
NEURODEGENERATIVE DISORDERS
The BBB is seen as a protector of the brain homeostasis since it
prevents the entry of several components from the blood into
the brain parenchyma. In particular, during MS and AD, the
mononuclear phagocytes from blood are also recruited via brain
chemokines, which allows entry of cells from the bloodstream
through the BBB (Britschgi and Wyss-Coray, 2007). Moreover,
these inflammatory and neurodegenerative disorders cause an
impairment of neural and synaptic functions due to the pro-
duction of neurotoxic compounds (Zlokovic, 2008; Mizee and
de Vries, 2013). MS and AD are quite distinct neurodegenera-
tive diseases but both affect the CNS, leading to degeneration
and consequently causing physical impairment and dementia,
respectively.
Furthermore, several studies have shown that microglia can
compromise BBB functions by the release of proinflammatory
cytokines, such as TNF-α and IL-6, leading to BBB disrup-
tion (Britschgi and Wyss-Coray, 2007). Here, we will discuss
the importance of microglia during the BBB breakdown in AD
and MS.
ALZHEIMER’S DISEASE
Alzheimer’s disease is recognized as one of the most common
causes of dementia that leads to impairment of memory, thinking
and behavior in humans (Zlokovic, 2008). The major patho-
logical features of this disease are the increased production and
deposition of amyloid-β (Aβ) and intracellular accumulation
of neurofibrillary tangle composed of hyperphosphorylated tau
protein, besides synapse and neuronal loss (Takeda et al., 2014).
Also, it is commonly accompanied by BBB dysfunction (Erickson
and Banks, 2013; Lyros et al., 2014). In the initial stage of AD,
there is loss of BBB homeostasis, leading to the production of
proinflammatory cytokines and suppressors of the cerebral blood
flow by ECs, which exacerbates synapse destruction, accumula-
tion and activation of microglia. Also, in the late phase of AD,
amyloid deposits are commonly observed in larger blood vessels
and smaller cerebral capillaries (Zlokovic, 2004, 2011).
Crosstalk between systemic and central innate immune sys-
tems by the release of inflammatory mediators is observed in AD
(Holmes, 2013). So, another role of BBB is the control of the
entrance of T lymphocytes into the brain (Town et al., 2005). In
AD patients, it was observed the presence of T cells in greater
numbers than in non-AD patients (Monson et al., 2014). It was
proved that the migration of T cells and immune cells into the
brain occurs under inflammatory conditions. In this study it was
shown that T cell migration into the brain through the BBB in
AD depends on the TNF-α expressed by microglia, which induce
the expression of MHC class I (MHC-I) on brain ECs (Yang et al.,
2013).
The microglial cells and astrocytes are the resident brain cells
responsible for the immune response in the brain, and it was
observed in AD brains the presence of activated microglia and
astrocytes around Aβ plaques, with the release of inflamma-
tory cytokines, such as IL-1 and IL-6, TNF-α and transforming
growth factor-β (TNF-β; Wyss-Coray, 2006; Zhou et al., 2012).
In AD, these cells can promote the clearance of Aβ, however,
if they are not able to do that, there is an accumulation of Aβ
deposits leading to neuronal death (Rogers et al., 2002). It has
already been shown that the elimination of Aβ from the brain
and the consequent impairment of microglial activation decrease
ROS, nitrogen compounds and also inflammatory cytokines
produced by microglial cells, which are correlated with the
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activation of ECs (Dickstein et al., 2006). Several studies using
animal models have further contributed with in vivo evidences
of the importance of microglia during AD progression. In the
study performed by El Khroury and collaborators using an
AD transgenic model, a CCL2-deficient APP/PS1 mouse, which
has a deficiency in the Ccr2 chemokine receptor and its lig-
and (CCL2) on microglia, they observed a regression in the
disease (El Khoury et al., 2007; Kiyota et al., 2013). More-
over, high levels of Aβ are correlated with production of CCL2
by microglia, which leads to BBB impairment (Roberts et al.,
2012).
On the other hand, it has been shown that LPS induces the
production of TNF-α in the brain by microglial cells, which
promotes BBB dysfunction and also causes neuronal cell death
by phagocytosis (Tanaka et al., 2006; Nishioku et al., 2010; Smith
et al., 2012; Neniskyte et al., 2014). Another cause of BBB break-
down is the accumulation of various molecules in the brain, such
as thrombin, which is released by ECs, leading to activation of
other components of the brain, like microglia and astrocytes. One
study found that brain microvessels collected from AD patients
produce high levels of thrombin, which directly affect neurons
by the induction of cell death, and indirectly affect activation of
microglia. Furthermore, it was shown that intracranial injection
of thrombin activates microglia, leading to the production of NO
and TNFα via JAK2-STAT3 signaling pathway, which induce BBB
disruption. Thus, it appears that thrombin causes a disruption of
BBB indirectly by activation of microglia (Huang et al., 2008a,b;
Yin et al., 2010; Grammas, 2011).
Thus, regarding all evidences described above, we can hypoth-
esize that microglia activation plays an important role during BBB
disruption, which substantiates the need to study other factors
correlated with inflammatory pathways, as potential targets of
new strategies to reduce microglial-dependent inflammation in
the brain of AD patients.
MULTIPLE SCLEROSIS
Multiple sclerosis is a chronic, progressive and neuroinflamma-
tory demyelinating disease of the CNS, which involves an energy
deficit, tissue remodeling, microglial activation and loss of BBB
integrity (Lassmann et al., 2012).
MS is often associated with the increase of BBB permeability,
and consequently inflammatory response causing the formation
of lesions and demyelization. Previous studies showed that sys-
temic inflammation contributes to the disease progression and the
activation of immune cells allows the infiltration of T and B cells
into the CNS, promoting the release of chemokines that in turn
stimulate the migration of more immune cells, leading to BBB dis-
ruption (Holman et al., 2011; Kooij et al., 2011; Larochelle et al.,
2011; Willis, 2011). Moreover, during inflammation and demyeli-
nation in MS, the activation of microglial cells lead to the release
of cytotoxic factors, such as NO and ROS, provoking myelin
damage, release of proinflammatory cytokines (IFNγ, TNF-α and
IL-1β), as well as chemokines (MCP-1), ultimately inducing BBB
disruption (Mahad and Ransohoff, 2003). Activated microglia
are known to express ROS-generating enzymes, such as NADPH
oxidase, which are responsible for degeneration of oligodendro-
cytes and increased BBB permeability by downregulating the
expression of VE-cadherin, occludin and claudin-5 proteins in
microvascular ECs (Fischer et al., 2012; Rochfort et al., 2014).
Hereupon, there are two different types of inflammation
in MS. The first consists in the initial response to the dis-
ease, involving the infiltration of CD4+ and CD8+ T-cells and
robust microglial activation; the second occurs due to the myelin
destruction, stimulating the secondary recruitment of T cells,
B cells and macrophages (Lassmann et al., 2012). There are two
well-established mouse models used to study MS, which have an
ineffectual immune response: Theiler’s Murine Encephalomyelitis
Virus-Induced Demyelinating Disease (TMEV-IDD; Rodriguez
et al., 1987) and experimental autoimmune encephalomyelitis
(EAE), where activation of microglia precedes infiltration of
peripheral macrophages and occurs before the onset of the disease
(Sriram and Steiner, 2005). In vivo imaging using two-photon
laser scanning microscopy (2PLSM) on EAE animal showed
dynamic interactions between BBB disruption and microglia acti-
vation. It was observed that microglial motility resulted from the
leakage of the plasma protein fibrinogen before the onset of MS
signs. In this event, fibrinogen induces the activation of microglia
and consequently the release of ROS, inducing axonal damage
(Davalos et al., 2012). Both in samples from patients with MS
and in an animal model for MS, EAE, it was observed a high
expression of MMPs. Microglia contributes to the inflammatory
process through the production of MMPs, such as MMP−1, −2,
−3, −9, and −19, which consequently leads to destabilization of
the BBB permeability (Weaver et al., 2005; van Horssen et al.,
2006).
Minocycline has been recognized as a microglia inhibitor (Li
et al., 2005; Defaux et al., 2011; Kobayashi et al., 2013; Miron
et al., 2013; Huang et al., 2014). Minocycline can reduce BBB
breakdown by preventing microglial production of glutamate,
MMPs, IL-1β and iNOS. The inhibition of microglial activa-
tion by minocycline favors the differentiation of oligodendro-
cyte precursors and immature oligodendrocytes. These cells are
responsible for remyelination of neurons, an important event for
improvement of MS condition (Li et al., 2005; Yenari et al., 2006;
Defaux et al., 2011; Miron et al., 2013). Recently published data
demonstrated that dipyridamole attenuates the expression of Toll-
like receptor stimulation-dependent cytokines and chemokines
in human microglia, reduces microglial activity in EAE mice,
and consequently decreases IL-1β, TNF-α and IL-6 expression,
which are responsible for increased BBB permeability (Sloka et al.,
2013).
Taking into account the literature reviewed about AD and
MS, we suggest that pharmacological modulation of microglial
activation may control the impairment of BBB in these diseases.
CONCLUDING REMARKS
Over the last years, many studies have been performed aiming at
understanding the role of BBB during ischemic injury, neurode-
generative disorders and infectious/inflammatory diseases. How-
ever, despite important advances made during the last decade,
the mechanisms involved in the multifaceted interactions between
the constituents of the NVU are not yet fully uncovered. In
particular, how activation of microglial cells may play a key role in
BBB disruption. When activated, microglia impair BBB function
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through the release of several inflammatory modulators leading
to a hyperpermeability condition, which is associated with several
brain disorders. In addition, the consequent infiltration of periph-
eral immune cells in turn affects microglia function. Microglial
activation may be one of the earliest phenomena involved in
the progression of these diseases. In this sense, the role of the
inflammatory response triggered by the activated microglia seems
to be essential to understand BBB dysfunction in CNS diseases.
Therefore, efforts should be directed towards the development of
new approaches focusing on microglia as a potential therapeutic
target.
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